Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Genentech Inc"


2 mentions found


July 19 (Reuters) - The president of Stanford University, one of the most prestigious U.S. schools, announced plans on Wednesday to resign his post after an independent review ordered by its board of trustees found flaws in his research as a neuroscientist. Those allegations were in connection with Alzheimer's disease research carried out when Tessier-Lavigne was the executive vice president of research drug discovery at the U.S. biotechnology company Genentech Inc. But the review of 12 research papers dating over two decades found that when concerns about the research were raised, "Tessier-Lavigne failed to decisively and forthrightly correct mistakes in the scientific record." As a result of the review, Tessier-Lavigne said he was going to retract three papers and correct another two. The board of trustees named Richard Saller, a professor in Stanford's Department of Classics, as interim president beginning Sept. 1.
Persons: Marc Tessier, Lavigne, Tessier, " Tessier, Richard Saller, Brad Brooks, Will Dunham, Donna Bryson Organizations: Stanford University, Stanford, University, Genentech Inc, Stanford's Department of Classics, Thomson Locations: U.S, Palo Alto , California, Lubbock , Texas
March 1 (Reuters) - Roche's Genentech Inc (ROGING.UL) sued Biogen MA Inc on Tuesday in San Francisco federal court, claiming Biogen owes additional patent royalties from worldwide sales of its blockbuster multiple-sclerosis and Crohn's disease drug Tysabri. Genentech's lawsuit said Biogen owes royalties for all the Tysabri that was produced using Genentech's patents before the patents expired, even if it was sold later. According to Genentech, Biogen has refused to pay royalties on any Tysabri sales since the patents expired more than four years ago. It said Biogen owes royalties for "most or all" of the Tysabri sold in "2019 and beyond," which it said was made with the patented technology before the patents expired. The case is Genentech Inc v. Biogen MA Inc, U.S. District Court for the Northern District of California, No.
Total: 2